- Investing.com
Apollo Hospitals Enterprise Limited, together with its subsidiaries, engages in the provision of healthcare services in India and internationally. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments. The company’s healthcare facilities comprise primary, secondary, and tertiary care, as well as specialty facilities. It offers services in cardiac sciences, orthopedics, oncology, neurosciences, emergency, robotic surgery, and transplants; and cardiology, neurology, gastroenterology, dermatology, ophthalmology, pediatric, endocrinology, gynecology, urology, nephrology, pulmonology, rheumatology, neurosurgery, radiology, plastic-surgery, neonatology, vascular-surgery, psychiatry, dentistry, ear, nose, and throat care, as well as genomic medicines. The company also provides other services, such as project consultancy, health insurance, medical colleges, medvarsity for e-learning, and research services. In addition, it operates pharmacies, primary care clinics, birthing centers, specialized birthing centers, dialysis centers, cradle and fertility centers, diabetes management centers, single specialty clinics, primary health centers and diagnostic chains, dental clinics, and daycare and home healthcare centers. Further, the company engages in the business of bio-banking of tissues. It serves through national retail healthcare centers and genomics institutes, as well as Apollo 24/7, a digital health mobile platform; and www.apollopharmacy.in, an online pharmacy. The company was incorporated in 1979 and is based in Chennai, India.
Metrics to compare | APLH | Peers Peers - average of corresponding metrics from companies closely matching APLH: METROPOLIS, NH, YATHARTH, KOVAI, JLHL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAPLHPeersSector |
---|---|---|---|---|
P/E Ratio | 89.8x | 70.8x | −0.6x | |
PEG Ratio | 1.25 | 1.79 | 0.00 | |
Price/Book | 14.2x | 8.4x | 2.6x | |
Price / LTM Sales | 5.2x | 6.6x | 3.3x | |
Upside (Analyst Target) | −0.1% | 2.3% | 45.3% | |
Fair Value Upside | Unlock | −14.6% | 6.1% | Unlock |